Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

http://www.wikidata.org/entity/Q34205476

about

Prospects for control of emerging infectious diseases with plasmid DNA vaccines.Poly(alkylene oxide) copolymers for nucleic acid delivery.Polymeric Materials for Gene Delivery and DNA Vaccination Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant Peptide vaccination in the presence of adjuvants in patients after hematopoietic stem cell transplantation with CD4+ T cell reconstitution elicits consistent CD8+ T cell responses.Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAX FDA guidance on prophylactic DNA vaccines: analysis and recommendations.Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein B antibody in serum.A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3.Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys.Prevention of maternal cytomegalovirus infection: current status and future prospects.Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients.Perinatal cytomegalovirus and varicella zoster virus infections: epidemiology, prevention, and treatment.Cytomegalovirus vaccines: at last, a major step forward Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.Cytomegalovirus: recent progress in understanding pathogenesis and control The March towards a Vaccine for Congenital CMV: Rationale and Models.Cytomegalovirus in hematopoietic stem cell transplant recipients The immune response to human CMV VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection.Update on the current status of cytomegalovirus vaccines.Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice.Biologic and immunologic effects of knockout of human cytomegalovirus pp65 nuclear localization signal Immunizations in solid organ and hematopoeitic stem cell transplant patients: A comprehensive review.Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery.A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.Congenital Cytomegalovirus: a "Now" Problem-No Really, Now CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency.Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles.Therapeutic strategies for the prevention and treatment of cytomegalovirus infection.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Cytomegalovirus vaccine: phase II clinical trial results.Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation.The history of vaccination against cytomegalovirus.Safety of ASP0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: an open-label phase 2 trial.

P2860

Q30380454-386D882F-283E-4CB3-A0A4-992998497A03 Q30418204-D2688C8A-216C-4D6A-B7FC-B9ECBEEBDB79 Q33565296-6492885F-8408-45CC-ABB2-FE0D30B7C918 Q33585524-BAFAA81B-7A26-402A-8B37-53C70A9DCF5E Q33703139-E6D42E29-F61C-47AF-892E-BDE770581EA9 Q33744024-25B6D09A-1F99-4A99-8B8B-52C76EFC7B37 Q33759465-AF16A388-346D-4E0C-9762-480D084EC5E1 Q33825662-CAD2F4BA-103E-4A0A-BE79-F43BD39CDBE5 Q33834057-B4D0B809-F2D8-42F8-BED3-1C1FBCB852D7 Q33877783-BD33115A-87CD-48F6-BC90-2502C1975F43 Q34272089-A77480B9-0381-452A-AAAC-92076C3CCC23 Q34349745-B40B763D-BAC8-4C7D-862F-C5A476880BA3 Q34432181-F718B482-E4E2-4E5D-A6CB-27D26147E7EA Q34667953-868CE7E6-624C-4A29-9C34-5802634682CB Q35270894-13B5B7AA-0503-42C7-B5F6-C8C53C982B39 Q35826628-E9496DD9-6DC0-4EC2-85B1-3DB6E1971734 Q35842287-9662A78A-2FC5-4B79-9575-1D70FEB8D7CB Q35895910-9EE2FBE1-D8E1-4549-9BED-931DCBD75963 Q35920807-5CE5E33B-A878-4EE3-93E5-1A86C84601B1 Q35922928-B2FDCCAB-2DB3-4913-BCF6-C21A643BB0D2 Q36517022-73E49CA0-DDD9-4EF1-AF04-3711ACBE0923 Q36517156-B575FF8B-3D85-4C6A-B2F0-9DD0CAFACF5B Q36678423-DF46E52D-47EF-451E-9E48-93A20B03D55F Q36694825-637DD8F1-5159-48F2-B48D-2AA40848AF06 Q36694861-488F3B6A-3C45-45B3-8F8D-774667D10E8E Q37213897-E02EF65B-D2F6-40C5-A88B-A3F6B5FC1DF4 Q37320197-62BDB556-30A4-4367-934B-145E5508D0C4 Q37351412-D8F9A4BE-600B-4AE2-A338-4F41D24E24AB Q37355242-4CCC9F16-746C-4B1A-A3D2-9D19D6B9F5E8 Q37390571-572BB967-2290-4398-A836-DCF5CFEE1328 Q37559627-94CE544C-8E42-4D92-9465-E078B34BAB62 Q37563598-40617D6C-F1E6-4974-B510-4E41C0A2A486 Q37700176-042016D8-6A37-46CC-BA78-888D6406A463 Q37730793-8FA8C1D2-31D7-4E1F-BA81-CAED04045C8B Q38014916-8E9AFEF3-48B7-4E67-BF2A-A112CF00597B Q38029953-1B4B46B7-C317-4506-BA7A-E0B41F2D5150 Q38166861-DEA87096-9CEF-4F67-93B8-826071437D02 Q38281851-D6C2E75F-17EB-42CB-922D-A0D4C4B5E0CF Q38384533-8CD88C9F-6416-4019-A493-25D6AB96D823 Q38385536-78EA88C3-9AA6-4513-B023-A1C5DDF24A82

P2860

Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

http://www.wikidata.org/entity/Q34205476

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@ast

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@en

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@nl

type

label

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@ast

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@en

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@nl

prefLabel

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@ast

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@en

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@nl

P1433

Q34205476-B5400B59-8120-46E8-920C-125F0E103A7C

P1476

Q34205476-08A566B4-D311-4F79-BD68-37E5EA3CACC0

P2093

Q34205476-02909E6A-E76A-4109-978D-5C222F886BEE

Q34205476-344D8F6B-CC2A-42B4-986A-B5BD01B8BB2C

Q34205476-568C466C-55CC-46F2-8C95-8A2C4F0427F1

Q34205476-5AD70761-054F-4910-AF88-E724E237218F

Q34205476-6F4314C8-FD1D-4DC0-BFA9-9C088B71AA39

Q34205476-792B5AD3-1256-46AB-8873-FA2B7D2213DD

Q34205476-7A8AD12E-4EEC-421E-A3BB-1D6B3B24BB8A

Q34205476-7DD8236B-3C30-4D13-A90E-E9C06C6D5F1A

Q34205476-83A5B82E-A05D-4678-8A36-FBDF1414263E

Q34205476-92CE5FEE-886F-49D1-B040-4CBD3E7F466F

P2860

Q34205476-03706328-7D7B-49D6-B4B9-39A44C353551

Q34205476-0D55F653-99C1-4ACA-9826-7F9C3DBA2B54

Q34205476-10251B83-B570-47B0-B833-02B0D5D3C07A

Q34205476-157ABAC9-2231-4D89-B468-EFB6429B1644

Q34205476-1FF1401D-6568-466F-A8E6-B2C40953459F

Q34205476-2396087C-9197-49C8-85E3-FD42E5046E62

Q34205476-3CDE34FB-BD50-4789-8927-EEB461219FC6

Q34205476-4B56FF3C-B5A1-4B25-8C63-AF20BC7E211D

Q34205476-4E03B489-CCEE-454D-B55F-0C19D10F0A81

Q34205476-59465CB6-3488-4144-9017-477871358F68

P304

Q34205476-2552DFFD-8764-46B2-9FE9-EBD4D5B60435

P31

Q34205476-15743439-D105-4F57-9151-1F78F170C218

P356

Q34205476-2C224F69-E345-49FE-AEE8-2DBFC1078687

P407

Q34205476-FA2AA219-1761-4C63-A0AB-16F2897E9476

P433

Q34205476-BCD44CEC-EAD3-4F90-8E9C-D65735746B94

P478

Q34205476-CC6E25C1-4332-4211-BD7B-B695D933889A

P50

Q34205476-A261BBA2-9A55-43F5-A36A-B7E6FA2D29E3

Q34205476-D1A7C1DF-C17C-4788-99D6-7819ABCE785E

P577

Q34205476-067B2FC3-51D4-4535-B48E-8705F57850CB

P5875

Q34205476-47A0BC4B-0FEA-4192-BB87-D2E184809278

P698

Q34205476-37AAA85D-C14F-4AD0-91FC-E6719FF7DE6F

P921

Q34205476-AE6C5204-B67E-41BB-8DAF-814CFF8700D8

P932

Q34205476-C94BD9BB-B4A5-45C1-A7FD-C596DFF6645F

P356

P1433

The Journal of Infectious Diseases

P1476

Safety and immunogenicity of a ...... ine in healthy adult subjects.

@en

P2093

Alain Rolland

http://www.w3.org/2001/XMLSchema#string

Christina Han

http://www.w3.org/2001/XMLSchema#string

David Kaslow

http://www.w3.org/2001/XMLSchema#string

Heather D Smith

http://www.w3.org/2001/XMLSchema#string

Jackie Kehler

http://www.w3.org/2001/XMLSchema#string

Janice M Brown

http://www.w3.org/2001/XMLSchema#string

Larry R Smith

http://www.w3.org/2001/XMLSchema#string

Linda Selk

http://www.w3.org/2001/XMLSchema#string

Luane Reyes

http://www.w3.org/2001/XMLSchema#string

Mary K Wloch

http://www.w3.org/2001/XMLSchema#string

P2860

Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion.

Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation.

Progress in cytomegalovirus vaccine development.

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction.

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag c

Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.

A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.

The rational design of an AIDS vaccine.

P304

1634-1642

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/588385

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

197

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5407328

http://www.w3.org/2001/XMLSchema#string

P698

18444883

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

2956065

http://www.w3.org/2001/XMLSchema#string